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Abstract
Myasthenia gravis (MG) is a rare, autoimmune neuromuscular junction disorder. Contemporary
prevalence rates approach 1/5,000. MG presents with painless, fluctuating, fatigable weakness
involving specific muscle groups. Ocular weakness with asymmetric ptosis and binocular diplopia is
the most typical initial presentation, while early or isolated oropharyngeal or limb weakness is less
common. The course is variable, and most patients with initial ocular weakness develop bulbar or
limb weakness within three years of initial symptom onset. MG results from antibody-mediated, T
cell-dependent immunologic attack on the endplate region of the postsynaptic membrane. In
patients with fatigable muscle weakness, the diagnosis of MG is supported by: 1. pharmacologic
testing with edrophonium chloride that elicits unequivocal improvement in strength; 2.
electrophysiologic testing with repetitive nerve stimulation (RNS) studies and/or single-fiber
electromyography (SFEMG) that demonstrates a primary postsynaptic neuromuscular junctional
disorder; and 3. serologic demonstration of acetylcholine receptor (AChR) or muscle-specific
tyrosine kinase (MuSK) antibodies. Differential diagnosis includes congenital myasthenic
syndromes, Lambert Eaton syndrome, botulism, organophosphate intoxication, mitochondrial
disorders involving progressive external ophthalmoplegia, acute inflammatory demyelinating
polyradiculoneuropathy (AIDP), motor neuron disease, and brainstem ischemia. Treatment must
be individualized, and may include symptomatic treatment with cholinesterase inhibitors and
immune modulation with corticosteroids, azathioprine, cyclosporine, and mycophenolate mofetil.
Rapid, temporary improvement may be achieved for myasthenic crises and exacerbations with
plasma exchange (PEX) or intravenous immunoglobulin (IVIg). Owing to improved diagnostic
testing, immunotherapy, and intensive care, the contemporary prognosis is favorable with less than
five percent mortality and nearly normal life expectancy.
Disease name
Myasthenia gravis, Autoimmune myasthenia gravis
Included diseases
Autoimmune myasthenia gravis (MG) encompasses all of
the immunologically-mediated disorders affecting the
endplate region of the postsynaptic neuromuscular junc-
tion. Nearly all of these disorders involve a loss of immu-
nological self-tolerance, though transitory neonatal MG is
a self-limited disorder that follows passive transfer of
maternal antibodies to the fetus. Congenital myasthenic
syndromes stem from genetic mutations that result in
abnormal neuromuscular transmission.
MG is termed ocular MG when weakness is exclusive to
the eyelids and extraocular muscles, and generalized MG
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when weakness extends beyond these ocular muscles.
Seropositive (SP) MG defines disease with circulating
antibodies to the acetylcholine receptor (AChR), while
seronegative (SN) patients lack these antibodies. Recently,
antibodies to muscle-specific tyrosine kinase (MuSK)
have been demonstrated in over 40% of patients with gen-
eralized, SN MG [1-5].
Definition and diagnostic criteria
MG remains one of the most challenging medical diag-
noses due to its fluctuating character and to the similarity
of its symptoms to those of other disorders. Although a
formal clinical classification system and research stand-
ards have been established for MG, [6] there are no widely
accepted formal diagnostic criteria. The most important
elements of diagnosis are clinical history and examination
findings of fluctuating and fatigable weakness, particu-
larly involving extraocular and bulbar muscles. A clinical
diagnosis may be confirmed by laboratory testing includ-
ing: 1. pharmacologic testing with edrophonium chloride
that elicits unequivocal improvement in strength; 2. elec-
trophysiologic testing with repetitive nerve stimulation
(RNS) studies and/or single-fiber electromyography
(SFEMG) that demonstrates a primary postsynaptic neu-
romuscular junctional disorder; or 3. by serological dem-
onstration of AChR or MuSK antibodies.
Epidemiology
Although MG is rare, prevalence rates for MG have
increased over time, likely due to improvements in diag-
nosis and treatment. Recent prevalence rates approach 20/
100,000 [7]. A wide range of incidence is reported with an
estimate of about 2.0 to 10.4/million/year in Virginia [8]
to 21.27/million/year in Barcelona, Spain [9]. The onset
of MG is influenced by gender and age in a bimodal fash-
ion. In patients younger than 40, women predominate
with a ratio of 7:3. In the fifth decade, new cases of MG are
evenly distributed between men and women. After age 50,
new cases of MG are slightly more common in men with
a ratio of 3:2 [10,11].
Pediatric MG is very rare. Juvenile MG is an autoimmune
disorder, while congenital MG results from genetic muta-
tions that impair neuromuscular transmission. Transient
neonatal MG is a self-limited disorder related to placental
antibody transfer in maternal autoimmune MG. It may be
difficult to make the distinction between juvenile MG and
congenital MG, particularly in the absence of AChR or
MuSK antibodies, or a clear history of ptosis and other
manifestations of hypotonia from the time of birth that
would suggest genetic disease. These issues are discussed
in depth by Andrews [12].
Clinical description
In MG, patients present with fluctuating and fatigable
weakness of specific muscle groups rather than with gen-
eralized fatigue or pain. The weakness is variable from day
to day and from hour to hour, but it is generally worse
later in the day. Sustained exercise and increased body
temperature may increase the degree of weakness. Ocular
weakness with asymmetric ptosis and binocular diplopia
is the most common initial presentation, while early or
isolated oropharyngeal or limb weakness is less common.
Ocular weakness presents as fluctuating, fatigable, and
sometimes alternating ptosis and binocular diplopia that
resolves with closing or covering one eye. Many patients
report difficulties with driving, reading, or watching tele-
vision. Bright lights may be quite bothersome. Retrospec-
tively, many patients report periods of intermittent
blurred vision before they were able to discern dual visual
images. Examination may demonstrate asymmetrical
weakness of multiple extraocular muscles that cannot be
attributed to a single cranial neuropathy. Pupillary func-
tion is normal. Ptosis may be elicited or increased with
sustained upgaze. In MG, ptosis is generally asymmetrical,
and it may be associated with ipsilateral frontalis muscle
contraction to help compensate for the weak levator
palpebrae. Excessive lid elevation or Cogan's lid twitch
sign may be observed when gaze is directed from down to
upward.
Dysthyroid (Graves) ophthalmopathy may coexist with
ocular MG. Although external ophthalmoplegia may
occur in either disorder, dysthyroid ophthalmopathy pro-
duces proptosis, not ptosis, owing to enlarged extraocular
muscles. The enlarged muscles may be demonstrated by
orbital magnetic resonance imaging (MRI).
Jaw closure muscles are frequently affected in MG, but
strength is usually normal in jaw opening muscles.
Patients may complain of difficulty in chewing candy or
tough meats, and some modify their diet to compensate
for this difficulty. Some patients assume a thoughtful rest-
ing posture by placing the thumb beneath the chin in
order to hold the jaw closed. The jaw closure muscles can
be examined by exerting several seconds of sustained
downward pressure on the chin while the patient attempts
to hold the jaw closed.
Many patients exhibit a depressed or expressionless facial
appearance. Actions such as whistling, using straws, or
inflating balloons may be impaired. A "myasthenic snarl"
may be observed when the patient attempts to smile. The
snarl follows contraction of the middle portion of the
upper lip while the upper mouth corners fail to contract.
On examination, many patients exhibit weak forced eye
closure that can easily be overcome by the examiner. Bell'sOrphanet Journal of Rare Diseases 2007, 2:44 http://www.OJRD.com/content/2/1/44
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phenomenon with upward and lateral rotation of the eyes
on attempted closure is observed when the examiner
defeats a patient's forced eye closure. Patients with mild
lower facial weakness develop a transverse pucker when
they attempt to hold air within inflated cheeks. With more
overt lower facial weakness, air readily escapes through
the lips when the cheeks are squeezed. In severe lower
facial weakness, the lips cannot be voluntarily opposed.
Oropharyngeal muscle weakness produces dysarthria and
dysphagia. With weakness of palatal muscles, nasal
speech develops as air escapes through the nose. This may
become increasingly apparent with prolonged speaking.
Liquid may also escape through the nose during
attempted swallowing with nasal regurgitation.
Myasthenic weakness of laryngeal muscles is associated
with a hoarse, breathy voice. Incomplete glottic closure
during swallowing may produce aspiration. Examination
may reveal reduced or absent palate elevation. Tongue
weakness may be demonstrated when the patient
attempts to protrude either cheek with the tongue against
the resistance of the examiner's finger applied to the
cheek. With marked tongue weakness, the patient may be
unable to protrude the cheek in the absence of applied
resistance by the examiner. With severe lingual weakness,
the tongue may not protrude beyond the lips. When
myasthenic tongue weakness is chronic, tongue atrophy
and triple furrowing may develop with accentuated
median and lateral lingual furrows.
Neck flexor and extensor muscles are often weak in MG.
Though the neck flexors are usually weaker, a "dropped
head syndrome" due to neck extensor muscle weakness
may occur. Although painless weakness is the rule in MG,
patients with neck extensor weakness may experience pos-
terior neck myalgias.
Limb weakness in MG may be associated with complaints
of difficulty performing overhead tasks with the arms, and
there may be difficulty climbing stairs due to lower
extremity weakness. Examination reveals asymmetrical
weakness involving any muscle group in the limbs,
though the deltoids, triceps brachii, wrist and finger exten-
sors, and foot dorsiflexors are often involved.
Etiology
Autoimmune MG results from antibody-mediated, T cell-
dependent immunologic attack on the postsynaptic mem-
brane of the neuromuscular junction. Abnormal neu-
romuscular transmission and clinical weakness in MG
result from the effects of antibodies that bind to various
epitopes of the skeletal muscle endplate region. In most
cases, antibodies bind to the main immunogenic region
of the α-subunit of the AChR, though MG patients with
antibodies to MuSK exhibit clinical weakness and electro-
physiologic findings that are quite similar to MG patients
with AChR antibodies. MuSK initiates aggregation of
AChRs at the muscle endplate during development, [2]
but the function of MuSK in mature skeletal muscle and
the pathophysiology of MG related to MuSK antibodies
are currently unknown.
In SP MG, binding of antibody to the AChR initiates
autoimmune attack on the endplate region. Subsequent
damage to the postsynaptic membrane results in simplifi-
cation of the normal, highly-infolded surface that is
accompanied by reduced number and density of AChR
[13]. The functional loss of AChRs reduces the probability
of successful neuromuscular transmission following
quantal release of acetylcholine by the motor nerve termi-
nal, resulting in clinical weakness in striated muscles.
MG and other autoimmune disorders result from the loss
of tolerance to self-antigens. T-lymphocyte tolerance to
self-antigens is established in the thymus, and thymic
abnormalities are often present in MG. Thymic hyperpla-
sia is observed in about 65% of MG patients, and thymo-
mas are present in about 10% of MG patients [14]. MG
patients with thymoma have more severe and generalized
weakness, higher AChR antibody titers, and more severe
electrophysiologic abnormalities. Accordingly, patients
with SN and ocular MG are less likely to have thymomas.
Most thymic tumors are benign, well differentiated, and
encapsulated. Patients with MG should undergo chest
computed tomography (CT) to exclude the presence of
thymoma. While thymoma resection is necessary to pre-
vent compromise of mediastinal structures, the benefit of
thymectomy for patients with non-thymomatous MG
remains uncertain.
Diagnostic methods
Pharmacologic testing
Edrophonium testing
Edrophonium chloride is an acetylcholinesterase inhibi-
tor with rapid onset (approximately 30 seconds) and
short duration (approximately 5 minutes) of pharmaco-
logic action. Edrophonium chloride temporarily
improves the safety factor of neuromuscular transmission
and may elicit improved strength in patients with abnor-
mal neuromuscular transmission. Edrophonium testing is
considered positive when unequivocal improvement in
strength follows intravenous administration of edropho-
nium. Development of increased weakness may also sug-
gest abnormal neuromuscular transmission. The primary
limitation of edrophonium testing relates to selection of
an objective muscle strength parameter for assessment.
Therefore, edrophonium testing is most useful in patients
who have significant ptosis or restricted extraocular move-
ments that can be graded objectively. In other muscles,
volition and the muscarinic effects of edrophonium mayOrphanet Journal of Rare Diseases 2007, 2:44 http://www.OJRD.com/content/2/1/44
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complicate strength measurement and render the test
uninterpretable.
The sensitivity of edrophonium testing has been esti-
mated to be about 86% for ocular MG and 95% for gener-
alized MG [15]. False positive edrophonium testing may
occur in other neurological conditions including lower
motor neuron disorders and brainstem tumors [16-19].
During testing, up to 10 mg of intravenous edrophonium
chloride may be administered. Because of the potential
for serious muscarinic side effects including bronchos-
pasm and bradycardia, atropine should be readily availa-
ble. Typical muscarinic side effects include increased
sweating, lacrimation, salivation, nausea, and diarrhea.
An incremental dosing schedule should be utilized with
one minute observation periods following each dose of
edrophonium. If muscle strength improves clearly within
one minute following any dose increment, the test is con-
sidered to be positive and the procedure is concluded.
This strategy reduces the risk of giving excessive edropho-
nium and producing untoward muscarinic side effects. An
initial 2 mg dose and subsequent doses of 2 mg, 3 mg, and
3 mg are given if needed.
Electrophysiologic testing
RNS studies
With low rates of motor nerve stimulation (2–5 Hz), RNS
depletes the immediate stores of acetylcholine at the neu-
romuscular junction. This reduces the safety factor and
probability of successful neuromuscular transmission. In
neuromuscular junction disorders, the safety factor is
reduced, and further reduction by RNS causes some end-
plate potentials to fail to reach depolarization threshold.
This results in a failure to elicit muscle fiber action poten-
tials. With a reduced number of individual muscle fiber
action potentials, the compound muscle action potential
(CMAP) becomes reduced in both amplitude and area
with a resulting decremental response.
In MG, RNS study findings are abnormal when the ampli-
tude of the fourth CMAP is reduced more than 10% from
the baseline value. This may not be present in stimulus
trains recorded following rest, but it may only develop in
trains collected subsequent to an exercise period as a con-
sequence of postactivation exhaustion. The sensitivity of
RNS is increased when recordings are made from clini-
cally weak muscles. Careful attention to proper technique
is important to avoid erroneous results. There must be
adequate immobilization of the stimulating and record-
ing electrodes, delivery of supramaximal stimuli, muscle
warming to 35°C, and withholding of acetylcholineste-
rase inhibitors for at least 12 hours prior to testing. In gen-
eral, proximal muscles including facial muscles, trapezius,
deltoid, and biceps brachii are more likely to exhibit
abnormal findings. In MG, when RNS studies are per-
formed in a hand and in a shoulder muscle, the overall
sensitivity is approximately 60%. RNS studies are rela-
tively more sensitive in generalized MG and relatively less
sensitive in ocular MG [20].
SFEMG
SFEMG is the most sensitive diagnostic test for detecting
abnormal neuromuscular transmission. In SFEMG, indi-
vidual muscle fiber action potentials generated by the
same motor neuron are recorded by a specialized concen-
tric needle with a 25 µm diameter recording surface and a
500 Hz high-frequency filter. In most normal muscles,
this arrangement facilitates recordings from two individ-
ual muscle fiber action potentials. The variability in time
interval between the firing of one muscle fiber potential
with relation to the other is termed the neuromuscular jit-
ter [21].
SFEMG should be performed in a clinically weak muscle
whenever possible. In many laboratories, the extensor dig-
itorum communis (EDC) is studied initially. If the find-
ings are normal in the EDC, a facial muscle should be
studied [22]. When a facial and a limb muscle are studied,
SFEMG is over 97% sensitive for detecting MG [23]. A
finding of normal jitter in a clinically weak muscle virtu-
ally excludes MG as a cause of weakness in that muscle.
However, SFEMG also demonstrates abnormal neu-
romuscular transmission related to other motor unit dis-
orders including motor neuropathic and myopathic
disorders. Normal SFEMG fiber density measurements
can aid in distinguishing primary disorders of neuromus-
cular transmission from other motor unit disorders such
as motor neuropathic or myopathic processes. In light of
its reduced specificity, SFEMG must be performed and
interpreted in the appropriate clinical context to avoid
false positive results due to diseases other than those pri-
marily affecting the neuromuscular junction. It is a time-
consuming test that requires special expertise and equip-
ment that are not available in all centers.
Serological testing
AChR antibodies
The AChR binding antibody assay utilizes purified human
skeletal AChRs incubated with patient serum immu-
noglobulin. The assay is very specific, and positive anti-
body studies confirm MG in a patient with appropriate
symptoms and clinical findings. AChR binding antibodies
are present in approximately 80% of patients with gener-
alized MG, but in only 55% of patients with ocular MG
[24,25]. About one-half of prepubertal children with MG
are SN [26]. Though relatively less sensitive than SFEMG,
AChR binding antibodies are highly specific for autoim-
mune MG. Rarely, false positive results in AChR binding
antibody assays have been observed in patients with otherOrphanet Journal of Rare Diseases 2007, 2:44 http://www.OJRD.com/content/2/1/44
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autoimmune diseases such as systemic lupus erythemato-
sus, rheumatoid arthritis, and inflammatory neuropathy.
False positive results have also been reported in motor
neuron disease, patients with thymoma without MG, and
relatives of patients with MG [27]. Some initially SN
patients may seroconvert within the first several months
of disease. Seroconversion may be identified in these
patients by repeating the AChR binding antibody studies
after six months of symptoms [28].
The AChR modulating antibody assay measures the degra-
dation rate of labeled AChRs from cultured human myo-
tubes. AChR blocking antibodies compete for the
acetylcholine binding site or allosterically inhibit binding
of radiolabelled α-bungarotoxin to the AChR [27]. The
AChR modulating and blocking antibody assays are prob-
ably useful only when the AChR binding antibody assay is
negative, since they increase diagnostic sensitivity only
slightly. Approximately 4% of patients with negative
AChR binding antibodies have an elevated AChR modu-
lating antibody assay, and approximately 1% of patients
with negative AChR binding antibodies demonstrate
increased AChR blocking antibodies [29].
Anti-striated muscle antibodies
Anti-striated muscle or anti-striational antibodies react
with contractile elements of skeletal muscle. They are
found in 30% of patients with adult-onset MG, and they
appear to be more common in patients with later disease
onset [30]. These antibodies may be useful as a serological
marker for thymoma in younger patients. Anti-striated
muscle antibodies have been demonstrated in 80% of
patients with thymoma in the absence of MG. Following
thymoma resection, a rise in anti-striated muscle antibody
titer may suggest recurrent tumor [30]. In one series, thy-
momas were demonstrated in 60% of patients with anti-
striated muscle antibodies and MG beginning before age
50, and in less than 2% of patients without these antibod-
ies [31].
MuSK antibodies
Antibodies to MuSK have been demonstrated recently in
about one third of patients with generalized SN MG.
Patients with MuSK MG are predominantly female and
may exhibit prominent bulbar, neck, shoulder girdle, and
respiratory weakness [1,2,4]. MuSK appears to facilitate
clustering of AChR at the end plate region in the develop-
ing neuromuscular junction, though the role of MuSK
antibodies in producing disease at mature neuromuscular
junctions has not yet been defined.
Other antibodies
Antibodies against the intracellular skeletal muscle pro-
tein titin may be present in patients with thymoma, but
they are also present in about half of patients with late-
onset MG without thymoma [32,33]. Ryanodine antibod-
ies are also associated with late-onset MG. Patients with
ryanodine antibodies may exhibit severe, treatment-resist-
ant MG associated with malignant thymomas [34].
Although the role for these antibodies in the diagnosis of
MG has yet to be determined, they may have prognostic
value and expedite chest imaging studies for detection of
thymoma.
Other testing
Chest computerized tomography (CT) should be per-
formed in patients with MG to exclude the presence of
thymoma. Chest CT is more sensitive than plain chest
radiographs for delineating anterior mediastinal masses,
and chest MRI does not improve diagnostic sensitivity.
Iodinated contrast agents have rarely precipitated signifi-
cant worsening of myasthenic weakness [35,36]. Though
this is an uncommon phenomenon [37], we do not rou-
tinely use iodinated contrast agents during chest CT stud-
ies performed to assess for thymoma. Since MG often co-
exists with other autoimmune disorders, particularly
autoimmune thyroid disease, patients should undergo
thyroid function testing along with testing for other
autoimmune disorders when clinically appropriate.
Summary
Pharmacologic testing with intravenous edrophonium is
sensitive when performed in patients with significant pto-
sis or external ophthalmoparesis. RNS studies may dem-
onstrate impaired neuromuscular transmission, especially
when performed recording from clinically weak muscles,
though they are relatively insensitive in ocular and in mild
generalized MG. SFEMG is the most sensitive laboratory
test for MG, although abnormal SFEMG findings may be
seen in motor neuropathic and in myopathic disorders.
Normal SFEMG findings in a clinically weak muscle
exclude a diagnosis of MG. In the clinical context of fluc-
tuating and fatigable weakness, AChR or MuSK antibodies
confirm the diagnosis of MG, though nearly half of
patients with ocular MG are SN.
Differential diagnosis
Differential diagnosis includes other disorders of the neu-
romuscular junction including Lambert Eaton syndrome,
botulism, congenital myasthenic syndromes, and tick
paralysis. In addition, acute inflammatory demyelinating
polyradiculoneuropathy (AIDP) and variants of AIDP
affecting cranial muscles such as the Miller-Fisher and cer-
vical-brachial-pharyngeal variants may simulate MG,
though the weakness does not have the same variability.
Mitochondrial neuromuscular disorders, particularly
those featuring external ophthalmoplegia and ptosis, may
simulate MG. However, the onset of symptoms is gradual,
and the weakness does not fluctuate greatly. Motor neu-
ron disease involving oropharyngeal weakness mayOrphanet Journal of Rare Diseases 2007, 2:44 http://www.OJRD.com/content/2/1/44
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appear similar to MG, though the presence of corticobul-
bar features and increased fiber density measurements on
SFEMG can assist in distinguishing these entities. Finally,
brainstem ischemia may simulate the fluctuating charac-
ter of MG, though unlike MG, consciousness, balance and
coordination, and sensation are often impaired.
Management
Treatment must be individualized to each patient with
MG. The overall goal is to reestablish or to approximate
normal clinical neuromuscular function while minimiz-
ing adverse effects. Few treatments have been subjected to
rigorous, prospective, placebo-controlled study in MG.
Factors to be considered in selecting treatment include the
distribution, duration, and severity of myasthenic weak-
ness and functional impairment, the risk for treatment
complications related to medical comorbidities, age, and
gender, and the ability of the patient to obtain medication
and comply with drug dosing schedules and toxicity mon-
itoring. In general, the increased risks related to long-term
immune modulation become more acceptable in more
severe MG to offset increased morbidity and mortality
related to uncontrolled disease. A detailed review of treat-
ment issues in autoimmune MG may be found elsewhere
[38].
Acetylcholinesterase inhibitors
Acetylcholinesterase inhibitors slow the hydrolysis of ace-
tylcholine at the neuromuscular junction and provide
temporary improvement in strength in many patients
with MG. Although acetylcholinesterase inhibitors were
among the earliest and remain one of the most widely pre-
scribed treatments for MG, there are no controlled clinical
trials of these agents in MG. Acetylcholinesterase inhibi-
tors are a symptomatic therapy for MG and do not retard
the underlying autoimmune attack on the neuromuscular
junction. The roles for acetylcholinesterase inhibitors in
MG include treatment of ocular and mild generalized dis-
ease, treatment in patients who cannot receive immune
suppression, and adjunctive treatment for patients receiv-
ing immunotherapy with residual or refractory
myasthenic weakness.
Effective dosing of acetylcholinesterase inhibitors reduces
myasthenic weakness, minimizes muscarinic medication
side effects, and must be individualized to each patient's
distribution of weakness and diurnal symptom fluctua-
tion. For example, patients with prominent dysphagia
may benefit by taking pyridostigmine 30 minutes before
meals and those with more symptoms in the afternoon
and evening may shift their dosing to later in the day to
better target symptoms. Pyridostigmine bromide is gener-
ally better tolerated than neostigmine bromide due to
fewer gastrointestinal side effects. A long-acting form of
pyridostigmine bromide is available, though it is
absorbed irregularly and tends to be overdosed. Initial
dosing of pyridostigmine bromide is usually 30 mg three
times a day and may be advanced to 90 mg three to four
times a day. Improvement in strength begins about 20 to
30 minutes after ingestion. Peak improvement is usually
observed at about 45 minutes after ingestion, and benefits
may last four hours or more.
The most salient side effects of acetylcholinesterase inhib-
itors relate to increased muscarinic activity and include
nausea, vomiting, abdominal cramping, diarrhea, dia-
phoresis, and increased lacrimation, salivation, and bron-
chial secretions. These dose dependent and self-limited
side effects may be treated with glycopyrrolate, and the
gastrointestinal side effects may be treated with diphenox-
ylate hydrochloride with atropine or loperamide hydro-
chloride.
Cholinergic crisis may develop with excessive dosing of
acetylcholinesterase inhibitors in patients with more
severe MG. In cholinergic crises, depolarization blockade
at diseased neuromuscular junctions results in increased
weakness, and increased muscarinic activity generates
copious oropharyngeal and bronchial secretions that may
obstruct the airway or be aspirated. Signs of cholinergic
crisis include weakness indistinguishable from
myasthenic weakness, muscle fasciculations, and symp-
toms of increased muscarinic activity including bradycar-
dia.
Corticosteroids
Corticosteroids are the most widely used immune modu-
lating agents for MG. Although the mechanism of action
in MG is unknown, corticosteroids have numerous effects
on the immune system including reduction of cytokine
production [39]. Corticosteroids are often used as the ini-
tial immunotherapy in patients with ocular and general-
ized MG, particularly in patients with unsatisfactory
responses to acetylcholinesterase inhibitors. These agents
may produce rapid improvement in MG, though they are
often associated with the liability of significant dose-
dependent side effects and occasionally elicit transient
and potentially serious myasthenic exacerbations within
the first two weeks of treatment. Prednisone treatment
produced significant improvement in strength within two
to three weeks in retrospective studies of MG [40,41], and
a Cochrane review cites significant short term benefit in
MG with corticosteroids [42]. Marked improvement or
remission was achieved in 80% MG patients in one large
series with a 3.1 month mean time to marked improve-
ment and a median time to maximum benefit between
five and six months [40].
The most reliable clinical responses to corticosteroids
occur with a high-dose daily regimen that is graduallyOrphanet Journal of Rare Diseases 2007, 2:44 http://www.OJRD.com/content/2/1/44
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tapered based on clinical improvement in strength. The
initial prednisone dose is typically 60–80 mg/day or 1.5–
2.0 mg/kg/day. This initial dose is maintained for two to
four weeks, and strength is reassessed. If strength is defi-
nitely improved, dosing is transitioned to an alternate day
schedule of 100–120 mg/alternate day to minimize adre-
nal suppression. Occasional patients are unable to toler-
ate an alternating-day regimen due to mood instability,
variation in MG, or difficult glycemic control in occa-
sional diabetic patients.
Myasthenic relapses may be delayed for three weeks after
reductions in corticosteroid dosing, and rapid tapering
may precipitate myasthenic exacerbations or crises. There-
fore, corticosteroid tapering must be slow, judicious, and
preceded by clinical reassessment of strength. Patients are
reassessed at four to eight week intervals, and if they have
maintained or improved strength and no recurrent symp-
toms, the prednisone dose is tapered by 10 mg/alternate
day to 30 mg/alternate day, and then by 5 mg/alternate
day to 20 mg/alternate day. Subsequent tapering by 2.5
mg/alternate day should be performed over longer inter-
vals of at least 12 weeks, since many patients will begin to
experience recurrent symptoms in this dosing range
unless they are being treated with another immune mod-
ulating agent.
The adverse effects of corticosteroids are numerous, well
known, and largely dose-dependent. These include:
hypertension, fluid retention, weight gain, potassium
loss, hyperlipidemia, diabetes mellitus, osteoporosis, gas-
tric ulceration, cataracts, glaucoma, moon facies, obesity,
acne, skin friability, juvenile growth suppression, and
mood/personality changes. Individuals at particular risk
for side effects include those who are diabetic or glucose
intolerant, obese, hypertensive, osteoporotic or post-men-
opausal, and those with affective or thought disorders. An
alternative immune modulator may be considered in such
patients.
A high protein, low fat, low carbohydrate, low sodium
diet is recommended to prevent untoward weight gain,
hyperlipidemia, and fluid retention. Serum electrolytes,
glucose, blood pressure, and weight are monitored peri-
odically during treatment. To minimize osteopenia, cal-
cium carbonate 1500 mg/day and vitamin D 600 IU/day
are recommended. In post-menopausal women, a base-
line bone density evaluation is performed and repeated
every six months during treatment. Before initiating treat-
ment with corticosteroids or any long-term immuno-
therapy, PPD testing should be considered as a screen for
tuberculosis.
Corticosteroid-related MG exacerbations may produce
transient but potentially serious increases in myasthenic
weakness in up to 15% of patients beginning treatment
with corticosteroids [40]. The increased weakness devel-
ops within 7–10 days after treatment begins and may last
for up to one week before strength improves [40,43].
Patients at greatest risk for morbidity related to this phe-
nomenon are those with more severe bulbar or general-
ized weakness and/or compromised respiratory function.
When beginning corticosteroid treatment in such
patients, strength and respiratory function should be
closely monitored. Plasma exchange (PEX) may be per-
formed prior to starting corticosteroids to circumvent or
minimize corticosteroid-related MG exacerbations. In
such cases, corticosteroids are initiated after a clear
improvement in strength attributable to PEX is docu-
mented.
An alternative dosing strategy of starting corticosteroids at
a low initial dose with gradual dose increases has been
advocated to reduce the risk for corticosteroid-related MG
exacerbations [44]. However, this strategy does not elimi-
nate the risk for exacerbation [45], and onset of strength
improvement is less predictable and may be significantly
delayed.
Azathioprine
Azathioprine is hepatically converted to 6-mercaptopu-
rine, an active anti-metabolite that blocks nucleotide syn-
thesis and T-lymphocyte proliferation. Azathioprine is an
effective agent for long-term immune modulation in MG
as a steroid sparing drug or as initial immunotherapy.
Compared to corticosteroids, azathioprine has a favorable
side effect profile for long-term use. However, the typi-
cally long delay of four to eight months from beginning
treatment with azathioprine to improved strength in MG
is a significant liability to its usefulness, particularly in
MG patients with progressive disease or functionally lim-
iting symptoms.
In a prospective, randomized, double-blind study com-
paring prednisolone with prednisolone plus azathioprine,
the prednisolone plus azathioprine treatment group
exhibited longer remissions, fewer treatment failures,
fewer side effects, and reduced maintenance doses of
prednisolone [46]. The initial dose is 50 mg/day is
increased by 50 mg/day every week to a target therapeutic
dose of 2–3 mg/kg/day.
Side effects include dose dependent myelosuppression
with macrocytic anemia, leukopenia, and thrombocyto-
penia, toxic hepatitis, and alopecia. Hypersensitivity pan-
creatitis represents a rare, but serious idiosyncratic
reaction, and patients with sustained abdominal pain tak-
ing azathioprine should be screened with serum amylase
and lipase assays. With long-term use, there is a small
increased risk for lymphoma [47].Orphanet Journal of Rare Diseases 2007, 2:44 http://www.OJRD.com/content/2/1/44
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Azathioprine is potentially teratogenic, and women of
child bearing potential using azathioprine should practice
effective contraception. An idiosyncratic allergic reaction
with rash, fever, nausea, vomiting, and abdominal pain
occurs in 10–15% patients within the first three weeks of
treatment [48,49]. The reaction resolves within one day of
stopping azathioprine, and will recur if the patient is
rechallenged with the drug.
Monitoring for myelosuppression is recommended with
weekly blood count and liver transaminase measurements
weekly for the first month of treatment, then monthly for
the first year, then every three months thereafter unless
the dosage is increased. Erythrocyte macrocytosis is
expected and acceptable within the therapeutic dosage
range. If white blood cell count (WBC) falls below 3500/
mm3, the dosage should be reduced, and if WBC falls
below 3000/mm3, azathioprine should be discontinued.
Cyclosporine
Cyclosporine exerts an immunomodulatory effect by
blocking interleukin-2 production and T lymphocyte pro-
liferation. Although effective, the use of cyclosporine in
MG has been limited by its nephrotoxicity and numerous
drug interactions. In light of this, cyclosporine is used in
MG as a steroid-sparing agent or for refractory generalized
disease. After therapeutic levels of cyclosporine are
achieved and maintained, improvement in strength is
usually observed within two months.
In a population of steroid-dependent patients with MG, a
randomized, double blind, placebo-controlled study of
cyclosporine demonstrated significantly improved
strength in the cyclosporine treatment group [50]. In a
long-term retrospective study, 96% MG patients
improved with cyclosporine treatment, and steroids could
be tapered or discontinued in 95% patients [51]. The typ-
ical cyclosporine dose is 2.5 mg/kg every 12 hours to
achieve a target serum trough level of 100–150 micro-
gram/L.
Side effects of cyclosporine include hypertension, neph-
ropathy, tremor, hirsutism, gingival hypertrophy, head-
aches, and nausea. Accordingly, relative contraindications
to cyclosporine include poorly controlled hypertension,
renal insufficiency or failure, malignancy, and inability to
comply with blood monitoring or medication precau-
tions.
Periodic monitoring is necessary to achieve therapeutic
trough cyclosporine levels and to prevent nephrotoxicity.
Assessments of blood pressure, serum creatinine and the
trough serum cyclosporine level should be performed fre-
quently until a stable, therapeutic dose of cyclosporine is
achieved and after new medications are begun that have
the potential to interact with cyclosporine.
Cyclosporine has problematic interactions with numer-
ous drugs that may result in nephrotoxicity, significant
increases in serum drug levels, and/or significant increases
or decreases in serum cyclosporine levels [52]. The most
common cyclosporine interactions and potential compli-
cations include non-steroidal anti-inflammatory agents
with impaired renal function, angiotensin converting
enzyme inhibitors eliciting hyperkalemia, and HMG CoA
reductase inhibitors precipitating cholesterol-lowering
agent myopathy.
Mycophenolate mofetil
Mycophenolate mofetil (MMF) is a relatively novel
immune modulator that selectively inhibits T and B lym-
phocyte proliferation by blocking purine synthesis exclu-
sively in lymphocytes. In human kidney transplant trials,
MMF exhibited minimal toxicity [53]. Given a paucity of
side effects, MMF is used in MG both as a steroid-sparing
agent and as initial immunotherapy in patients at risk for
corticosteroid complications. Improved strength is
observed within about two months after reaching a thera-
peutic dose of MMF.
Significantly improved strength in MG patients taking
MMF has been demonstrated in a retrospective case series
[54], in an open label pilot study in steroid dependent or
refractory MG [55], and in a double-blind placebo control
pilot trial in MG [56].
However, in a recently concluded multi-center, rand-
omized, controlled trial of low dose prednisone versus
low dose prednisone with MMF, there was no clinically
significant benefit in MG patients treated with MMF com-
bined with low dose prednisone beyond that observed in
MG patients treated with low dose prednisone only dur-
ing the initial three month trial period. Analysis of the
open label phase of this study is currently pending [57].
The standard MMF dosage in MG is 1000–1500 mg twice
a day. Higher doses are associated with myelosuppres-
sion, and periodic blood counts are performed during
treatment as surveillance against leukopenia or anemia.
There is a small increased risk for lymphoproliferative dis-
orders in transplant patients, and a case of central nervous
system (CNS) lymphoma has been documented in a
patient with MG after three years of MMF treatment [58].
Side effects are relatively mild. In one series, diarrhea,
abdominal pain, and nausea were reported in 27%
patients, though only 6% patients discontinued MMF due
to these side effects [59].Orphanet Journal of Rare Diseases 2007, 2:44 http://www.OJRD.com/content/2/1/44
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Plasma exchange
PEX is used in MG to achieve rapid, temporary improve-
ment in strength. During PEX, plasma containing AChR
antibodies is separated from whole blood and replaced by
albumin or fresh frozen plasma. The procedure requires
catheterizing large caliber veins. Although many patients
have large antecubital veins that may be accessed serially
for PEX procedures, some patients require placement of
large bore dual lumen central venous catheters. PEX is
generally reserved for short-term treatment to achieve
rapid strength improvement in myasthenic exacerbations
or crises, to prepare patients for thymectomy or another
surgical procedure, to prevent steroid-related MG exacer-
bations in susceptible patients beginning corticosteroid
treatment, and for rare patients refractory to all other
treatments. An National Institutes of Health (NIH) con-
sensus statement supports use of PEX in these instances
[60]. Although there have been no controlled clinical tri-
als of PEX in MG, several series demonstrate significantly
improved strength in most patients with severe MG
undergoing PEX [61-63]. PEX trials in MG are summa-
rized in a Cochrane review [64].
Typically, a PEX series consists of five to six exchanges of
two to three liters on alternate days. Most PEX complica-
tions are related to issues of vascular access, particularly to
complications of large bore central venous catheters.
Excessive fluid volume shifts during the procedure may
result in hypotension or fluid overload and congestive
heart failure. Sepsis and hypotension are contraindica-
tions to PEX.
Improved strength is generally observed after the second
or third exchange procedure in most MG patients. Unless
another form of treatment is employed, the improved
strength is temporary and lasts only a few weeks at best.
Intravenous immunoglobulin
IVIg has been utilized in a number of autoimmune neu-
romuscular disorders including acute and chronic inflam-
matory polyneuropathy. It is thought to act by down
regulation of autoantibodies and/or induction of anti-idi-
otypic antibodies. In MG, IVIg may provide short-term
improvement in strength for MG exacerbations and crises,
for surgical preparation in patients who are poor PEX can-
didates because of vascular access issues, and in patients
with septicemia.
A number of studies demonstrate efficacy for IVIg in MG.
A small randomized, controlled trial of IVIg 1.2 and 2.0
gm/kg compared with PEX in MG patients with exacerba-
tion or crisis showed comparable efficacy between the
PEX and IVIg treatment groups [65]. Another retrospective
multicenter study demonstrated that PEX was better than
IVIg in ability to successfully extubate patients in crisis at
two weeks and in functional outcome at one month [66].
However, the PEX groups in both studies sustained more
cardiovascular and infectious complications. Although
the magnitude of responses appears to be comparable
between PEX and IVIg, treatment failures have been
reported to IVIg with subsequent response to PEX [67].
IVIg trials in MG are summarized in a Cochrane review
[68]. The time to improved strength following IVIg infu-
sions is somewhat variable, as demonstrated by a trial of
IVIg given to prepare MG patients for thymectomy in
which maximal response was delayed by up to 19 days
[69]. IVIg is generally administered as 10% solution, and
the standard dosage is 2 gm/kg over two to five days.
However, one randomized trial found no added benefit
for doses of 2 gm/kg over 1 gm/kg for MG exacerbations
[70]. Pretreatment with acetaminophen and diphenhy-
dramine may reduce the frequency and severity of idio-
syncratic reactions.
Side effects include volume overload, particularly for
patients with cardiomyopathy or valvular heart disease,
solute-induced renal failure, especially in patients with
preexisting renal insufficiency or diabetic nephropathy
[71], and idiosyncratic reactions such as fever, chills, nau-
sea, vomiting, vascular headaches, and aseptic meningitis.
High infusion rates may be associated with thrombosis
and stroke [72]. Serum immunoglobulin quantitation to
screen for IgA deficiency is recommended, since IVIg prep-
arations contain traces of IgA.
Thymectomy
Thymectomy has been widely performed in an effort to
achieve medication-free remission in MG following Bla-
lock's early observations of remissions following thymec-
tomy in non-thymomatous MG [73,74]. To date, there
have been no prospective, randomized studies completed
to assess the technique or effectiveness of thymectomy in
non-thymomatous MG. Fortunately, a large, international
multicenter trial is currently enrolling subjects to assess
the benefit of thymectomy in non-thymomatous MG
[75,76]. An evidence-based review was recently performed
to address the role of thymectomy in the management of
MG, and outcomes of thymectomy in controlled, nonran-
domized studies were systematically reviewed [77].
Although patients undergoing thymectomy in non-thy-
momatous MG were more likely to achieve medication-
free remission, become asymptomatic, or exhibit clinical
improvement, the association between thymectomy and
improved outcomes could attribute either to thymectomy
or to differences in the study populations. Therefore, in
non-thymomatous MG, thymectomy should be consid-
ered as an option to increase the probability of remission
or improvement [77]. The response to thymectomy is not
immediate and may be delayed for several years [78-80].Orphanet Journal of Rare Diseases 2007, 2:44 http://www.OJRD.com/content/2/1/44
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Controversies related to thymectomy in non-thymoma-
tous MG include the ideal timing of the procedure with
respect to MG onset, course, and patient age, the optimal
surgical technique, whether patients with exclusively ocu-
lar MG should undergo thymectomy, and whether
patients with SN or MuSK MG benefit from thymectomy.
Because of increased surgical risk and reduced life span,
thymectomy is rarely performed in patients at greater than
age 60 years for non-thymomatous MG. There is evidence
to suggest that the best clinical responses occur if thymec-
tomy is performed early in the course of MG [81], though
this may attribute to a non-linear remission rate [77], as
remission is more likely to occur shortly after diagnosis
rather than with more chronic disease [82]. The role for
thymectomy in non-thymomatous ocular MG is also
uncertain [83,84]. In MuSK MG, no thymomas have been
reported to date, and findings in recent clinical series raise
doubt about benefits of thymectomy in MuSK MG
patients [1,2,4].
Thymectomy may be performed via several approaches.
Though more invasive than other approaches, a com-
bined transsternal-transcervical technique is considered to
be optimal as it provides the widest exposure for complete
removal of thymic tissue that may be widely distributed in
mediastinum and neck [85]. Surgical techniques for
thymectomy have been reviewed by Jaretzki and col-
leagues [86]. Preoperative PEX or IVIg is performed to
improve strength in patients with moderate or severe gen-
eralized or bulbar MG or in patients with MG-related res-
piratory insufficiency [87]. In contemporary series of
thymectomy for MG, mortality is less than 1%. Complica-
tions include respiratory failure due to myasthenic crisis
in 6%, infection in 11%, and recurrent laryngeal or
phrenic nerve injury in 2% [88].
Prognosis
Most patients develop initial symptoms of extraocular
muscle weakness with asymmetric ptosis and diplopia.
The course is frequently variable, particularly within the
first year of disease. Nearly 85% of patients with initial
ocular symptoms progress to develop weakness of bulbar
and limb muscles within the first three years [10,89]. Ini-
tial presentations with oropharyngeal and limb weakness
are less common. Maximum disease severity is reached
within the first year in almost two-thirds of patients [11].
Myasthenic crisis, or respiratory failure due to myasthenic
weakness occurs in about 20% of patients, usually within
the first year of illness [90,91]. Myasthenic symptoms and
signs may worsen in the setting of systemic illness, partic-
ularly viral upper respiratory infections, thyroid disease,
pregnancy, increased body temperature, and exposure to
drugs that impair neuromuscular transmission (Table 1)
[23,92].
Early in the course of MG, symptoms may fluctuate and
occasionally remit, although such remissions are rarely
permanent [89,93]. Three major stages of generalized MG
have been proposed [94]. An active stage characterized by
relapses and remissions lasting approximately seven years
is followed by an inactive stage lasting about 10 years. The
inactive stage is characterized by less disease volatility,
though patients may experience exacerbations related to
intercurrent illnesses, pregnancy, or exposure to medica-
tions that compromise neuromuscular transmission. In
the ultimate stage of "burned-out" disease, untreated
weakness may become fixed in association with muscle
atrophy.
Prior to the widespread use of immunomodulators, prog-
nosis for patients with MG was grim with about 30% mor-
tality [89]. Along with advances in mechanical ventilation
and intensive care, immunotherapy has been one of the
major factors contributing to improved outcome in MG,
and contemporary disease-specific mortality is less than
5% [95].
Unresolved questions
There are several contemporary issues related to MG that
remain to be resolved. Issues pertaining to MuSK MG
include determining the pathophysiologic role of MuSK
antibodies in the development of MG, whether the immu-
nological attack on the endplate region in MuSK MG is
similar to that of SP MG, and whether thymectomy bene-
fits patients with MuSK MG. The benefit of thymectomy in
non-thymomatous SP MG is poorly defined at present,
and an international, multicenter trial is currently being
Table 1: Medications that may exacerbate weakness in myasthenia gravis
D-penicillamine
Curare and related drugs
Selected antibiotics including aminoglycosides (tobramycin, gentamycin, kanamycin, neomycin, streptomycin), macrolides (erythromycin, 
azithromycin, telithromycin [Ketek®]), and fluoroquinolones (ciprofloxacin, norfloxacin, ofloxacin, pefloxacin)
Quinine, quinidine or procainamide
Beta-blockers
Calcium channel blockers
Magnesium salts (milk of magnesia, some antacids, tocolytics)
Botulinum toxinOrphanet Journal of Rare Diseases 2007, 2:44 http://www.OJRD.com/content/2/1/44
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undertaken to determine whether and to what degree
thymectomy is beneficial in non-thymomatous disease
[76]. Whether corticosteroid treatment begun early in the
course of ocular MG can prevent generalization has yet to
be demonstrated. Finally, it remains to be determined
whether and under what circumstances can immune
modulation be discontinued without significant risk of
relapse in MG patients that have achieved remission with
immunotherapy.
References
1. Evoli A, Tonali PA, Padua L, Lo Monaco M, Scuderi F, Batocchi AP,
Marino M, Bartoccioni E: Clinical correlates with anti-MuSK anti-
bodies in generalized seronegative myasthenia gravis.  Brain
2003, 126:2304-2311.
2. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A:
Auto-antibodies to the receptor tyrosine kinase MuSK in
patients with myasthenia gravis without acetylcholine recep-
tor antibodies.  Nat Med 2001, 7:365-368.
3. McConville J, Farrugia ME, Beeson D, Kishore U, Metcalfe R, Newsom-
Davis J, Vincent A: Detection and characterization of MuSK anti-
bodies in seronegative myasthenia gravis.  Ann Neurol 2004,
55:580-584.
4. Sanders DB, El-Salem K, Massey JM, McConville J, Vincent A: Clinical
aspects of MuSK antibody positive seronegative myasthenia
gravis (SNMG).  Neurology 2003, 60:1978-1980.
5. Scuderi F, Marino M, Colonna L, Mannella F, Evoli A, Provenzano C,
Bartoccioni E: Anti-P110 autoantibodies identify a subtype of
"seronegative" myasthenia gravis with prominent oculobul-
bar involvement.  Lab Invest 2002, 82:1139-1146.
6. Jaretzki A III, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS,
Sanders DB: Myasthenia gravis: Recommendations for clinical
research standards.  Neurology 2000, 55:16-23.
7. Phillips LH 2nd: The epidemiology of myasthenia gravis.  Ann NY
Acad Sci 2003, 998:407-412.
8. Phillips LH 2nd, Torner JC: Epidemiologic evidence for a changing
natural history of myasthenia gravis.  Neurology 1996,
47:1233-1238.
9. Aragones JM, Bolibar I, Bonfill X, Mummany A, Alonso F, Illa I:
Myasthenia gravis. A higher than expected incidence in the
elderly.  Neurology 2003, 60:1024-1026.
10. Grob D: Course and management of myasthenia gravis.  JAMA
1953, 153:529-532.
11. Grob D, Brunner NG, Namba T: The natural course of myasthe-
nia gravis and effects of therapeutic measures.  Ann NY Acad Sci
1981, 377:652-669.
12. Andrews PI: Autoimmune myasthenia gravis in childhood.
Semin Neurol 2004, 24:101-110.
13. Santa T, Engel AG, Lambert EH: Histomeric study of neuromuscu-
lar junction ultrastructure I. Myasthenia gravis.  Neurology 1972,
22:71-82.
14. Namba T, Brunner NG, Grob D: Myasthenia gravis in patients
with thymoma, with particular reference to onset after
thymectomy.  Medicine 1978, 57:411-433.
15. Phillips LH 2nd, Melnick PA: Diagnosis of myasthenia gravis in the
1990s.  Semin Neurol 1990, 10:62-69.
16. Dirr LY, Donofrio PD, Patton JF, Troost BT: A false-positive edro-
phonium test in a patient with a brainstem glioma.  Neurology
1989, 39:865-867.
17. Moorthy G, Behrens MM, Drachman DB, Kirkham TH, Knox DL, Miller
NR, Slamovitz TL, Zinreich SJ: Ocular pseudomyasthenia or ocu-
lar myasthenia "plus": A warning to clinicians.  Neurology 1989,
39:1150-1154.
18. Mulder DW, Lambert EH, Eaton LM: Myasthenic syndrome in
patients with ALS.  Neurology 1959, 9:627-631.
19. Ragge NK, Hoyt WF: Midbrain myasthenia: fatigable ptosis, lid
twitch sign, and ophthalmoparesis from a dorsal midbrain gli-
oma.  Neurology 1992, 42:917-919.
20. Howard JF, Sanders DB, Massey JM: The electrodiagnosis of
myasthenia gravis and the Lambert-Eaton myasthenic syn-
drome.  Neurol Clin 1994, 12:305-330.
21. Stålberg EV, Trontelj JV: Single fiber electromyography: studies in healthy
and diseased muscle 2nd edition. New York: Raven Press; 1994. 
22. AAEM Quality Assurance Committee, American Association of Elec-
trodiagnostic Medicine: Practice parameter for repetitive nerve
stimulation and single fiber EMG evaluation of adults with sus-
pected myasthenia gravis or Lambert-Eaton myasthenic syn-
drome: Summary statement.  Muscle Nerve 2001, 24:1236-1238.
23. Sanders DB, Howard JF: Disorders of neuromuscular transmis-
sion.  In Neurology in clinical practice 1st edition. Edited by: Bradley WG,
Daroff RB, Fenichel GM, Marsden CD. Boston: Butterworth-Heine-
mann; 1991:1819-1842. 
24. Lindstrom J: An assay for antibodies to human acetylcholine
receptor in serum from patients with myasthenia gravis.  Clin
Immunol Immunopathol 1977, 7:36-43.
25. Vincent A, Newsom-Davis J: Acetylcholine receptor antibody as a
diagnostic test for myasthenia gravis: results in 153 validated
cases and 2967 diagnostic assays.  J Neurol Neurosurg Psychiatry
1985, 48:1246-1252.
26. Andrews PI, Massey JM, Sanders DB: Acetylcholine receptor anti-
bodies in juvenile myasthenia gravis.  Neurology 1993, 43:977-982.
27. Lennon VA: Serological diagnosis of myasthenia gravis and
Lambert-Eaton myasthenic syndrome.  In Handbook of Myasthe-
nia Gravis and Myasthenic Syndromes Edited by: Lisak RP. New York:
Marcel-Dekker; 1994:149-164. 
28. Sanders DB, Andrews I, Howard JF, Massey JM: Seronegative
myasthenia gravis.  Neurology 1997, 48(Suppl 5):S40-S45.
29. Howard FM Jr, Lennon VA, Finley J, Matsumoto J, Elveback LR: Clinical
correlations of antibodies that bind, block, or modulate
human acetylcholine receptors in myasthenia gravis.  Ann NY
Acad Sci 1987, 505:526-538.
30. Cikes N, Momoi MY, Williams CL, Howard FM Jr, Hoagland HC, Whit-
tingham S, Lennon VA: Striational autoantibodies: Quantitative
detection by enzyme immunoassay in myasthenia gravis, thy-
moma, and recipients of D-penicillamine or allogeneic bone
marrow.  Mayo Clin Proc 1988, 63:474-481.
31. Sanders DB, Massey JM: The diagnostic utility of anti-striational
antibodies in myasthenia gravis [abstract].  Neurology 2002,
58:A229.
32. Somnier FE, Engel PJ: The occurrence of anti-titin antibodies and
thymomas: A population survey of MG 1970–1999.  Neurology
2002, 59:92-98.
33. Yamamoto AM, Gajdos P, Eymard B, Tranchant C, Warter JM, Gomez
L, Bourquin C, Bach JF, Garchon HJ: Anti-titin antibodies in
myasthenia gravis. Tight association with thymoma and het-
erogeneity of nonthymoma patients.  Arch Neurol 2001,
58:885-890.
34. Mygland A, Aarli JA, Matre R, Gilhus NE: Ryanodine receptor anti-
bodies related to severity of thymoma associated myasthenia
gravis.  J Neurol Neurosurg Psychiatry 1994, 57:843-846.
35. Chagnac Y, Hadanin M, Goldhammer Y: Myasthenic crisis after
intravenous administration of iodinated contrast agent.  Neu-
rology 1985, 35:1219-1220.
36. Canal N, Franceschi M: Myasthenic crisis precipitated by iotha-
lamic acid.  Lancet 1983, 1:1288.
37. Frank JH, Cooper GW, Black WC, Phillips LH: Iodinated contrast
agents in myasthenia gravis.  Neurology 1987, 37:1400-1402.
38. Juel VC, Massey JM: Autoimmune myasthenia gravis: Recom-
mendations for treatment and immunologic modulation.  Curr
Treat Options Neurol 2005, 7:3-14.
39. McEwen BS, Biron CA, Brunson KW, Bulloch K, Chambers WH, Dhab-
har FS, Goldfarb RH, Kitson RP, Miller AH, Spencer RL, Weiss JM: The
role of adrenocorticoids as modulators of immune function in
health and disease: neural, endocrine and immune interac-
tions.  Brain Res Rev 1997, 23:79-133.
40. Pascuzzi RM, Coslett HB, Johns TR: Long-term corticosteroid
treatment of myasthenia gravis: Report of 116 patients.  Ann
Neurol 1984, 15:291-298.
41. Johns TR: Long-term corticosteroid treatment of myasthenia
gravis.  Ann NY Acad Sci 1987, 505:568-583.
42. Schneider-Gold C, Gajdos P, Toyka KV, Hohlfeld RR: Corticoster-
oids for myasthenia gravis.  Cochrane Database of Systematic Reviews
2005, 2:CD002828. 
43. Miller RG, Milner-Brown HS, Mirka A: Prednisone-induced wors-
ening of neuromuscular function in myasthenia gravis.  Neurol-
ogy 1986, 36:729-732.Orphanet Journal of Rare Diseases 2007, 2:44 http://www.OJRD.com/content/2/1/44
Page 12 of 13
(page number not for citation purposes)
44. Seybold ME, Drachman DB: Gradually increasing doses of pred-
nisone in myasthenia gravis: reducing the hazards of treat-
ment.  N Engl J Med 1974, 290:81-84.
45. Sghirlanzoni A, Peluchetti D, Mantegazza R, Fiacchino F, Cornelio F:
Myasthenia gravis: prolonged treatment with steroids.  Neurol-
ogy 1984, 34:170-174.
46. Palace J, Newsom-Davis J, Lecky B: A randomized double-blind
trial of prednisolone alone or with azathioprine in myasthenia
gravis. Myasthenia Gravis Study Group.  Neurology 1998,
50:1778-1783.
47. Herrllinger U, Weller M, Dichgans J, Melms A: Association of pri-
mary central nervous system lymphoma with long-term aza-
thioprine therapy for myasthenia gravis.  Ann Neurol 2000,
47:682-683.
48. Hohlfeld R, Michels M, Heininger K, Besinger U, Toyka KV: Azathio-
prine toxicity during long-term immunosuppression of gener-
alized myasthenia gravis.  Neurology 1988, 38:258-261.
49. Kissel JT, Levy RJ, Mendell JR, Griggs RC: Azathioprine toxicity in
neuromuscular disease.  Neurology 1986, 36:35-39.
50. Tindall RS, Phillips JT, Rollins JA, Wells L, Hall K: A clinical therapeu-
tic trial of cyclosporine in myasthenia gravis.  Ann NY Acad Sci
1993, 681:539-551.
51. Ciafaloni E, Nikhar NK, Massey JM, Sanders DB: Retrospective anal-
ysis of the use of cyclosporine in myasthenia gravis.  Neurology
2000, 55:448-450.
52. Sanders DB, Howard JF: Disorders of neuromuscular transmis-
sion.  In Neurology in clinical practice 3rd edition. Edited by: Bradley WG,
Daroff RB, Fenichel GM, Marsden CD. Boston: Butterworth-Heine-
mann; 2000:2167-2185. 
53. Sollinger HW, Renal Transplant Mycophenolate Mofetil Study Group:
Mycophenolate mofetil for the prevention of acute rejection
in primary cadaveric renal allograft recipients. U.S. Renal
Transplant Mycophenolate Mofetil Study Group.  Transplanta-
tion 1995, 60:225-232.
54. Chaudhry V, Cornblath DR, Griffin JW, O'Brien R, Drachman DB:
Mycophenolate mofetil: A safe and promising immunosup-
pressant in neuromuscular diseases.  Neurology 2001, 56:94-96.
55. Ciafaloni E, Massey JM, Tucker-Lipscomb B, Sanders DB: Mycopheno-
late mofetil for myasthenia gravis: An open-label pilot study.
Neurology 2001, 56:97-99.
56. Meriggioli MN, Rowin J, Richman JG, Leurgans S: Mycophenolate
mofetil for myasthenia gravis: A double-blind, placebo-con-
trolled pilot study.  Ann NY Acad Sci 2003, 998:494-499.
57. Sanders D, McDermott M, Thornton C, Tawil A, Barohn R, the Muscle
Study Group: A trial of mycophenolate mofetil (MMF) with
prednisone as initial immunotherapy in myasthenia gravis
(MG) [abstract].  Neurology 2007, 68:A107.
58. Vernino S, Salomao DR, Habermann TM, O'Neill BP: Primary CNS
lymphoma complicating treatment of myasthenia gravis with
mycophenolate mofetil.  Neurology 2005, 65:639-641.
59. Meriggioli MN, Ciafaloni E, Al-Hayk KA, Rowin J, Tucker-Lipscomb B,
Massey JM, Sanders DB: Mycophenolate mofetil for myasthenia
gravis: an analysis of efficacy, safety, and tolerability.  Neurology
2003, 61:1438-1440.
60. NIH Consensus Conference: The utility of therapeutic plas-
mapheresis for neurological disorders.  JAMA 1986,
256:1333-1337.
61. Pinching AF, Peters DK, Newsom-Davis J: Remission of myasthenia
gravis following plasma exchange.  Lancet 1976, 2:1373-1376.
62. Dau PC, Lindstrom JM, Cassel CK, Denys EH, Shev EE, Spitler LE: Plas-
mapheresis and immunosuppressive drug therapy in
myasthenia gravis.  N Engl J Med 1977, 297:1134-1140.
63. Antozzi C, Gemma M, Regi B, Berta E, Confalonieri P, Peluchetti D,
Mantegazza R, Baggi F, Marconi M, Fiacchino F, et al.: A short plasma
exchange protocol is effective in severe myasthenia gravis.  J
Neurol 1991, 238:103-107.
64. Gajdos P, Chevret S, Toyka K: Plasma exchange for myasthenia
gravis.  Cochrane Database of Systematic Reviews 2002, 4:CD002275. 
65. Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C: Clinical trial
of plasma exchange and high-dose intravenous immunoglob-
ulin in myasthenia gravis. Myasthenia Gravis Clinical Study
Group.  Ann Neurol 1997, 41:789-796.
66. Qureshi AI, Choudhry MA, Akbar MS, Mohammad Y, Chua HC, Yahia
AM, Ulatowski JA, Krendel DA, Leshner RT: Plasma exchange ver-
sus intravenous immunoglobulin treatment in myasthenic cri-
sis.  Neurology 1999, 52:629-632.
67. Stricker RB, Kwiatkowska BJ, Habis JA, Kiprov DD: Myasthenic cri-
sis. Response to plasmapheresis following failure of intrave-
nous gamma-globulin.  Arch Neurol 1993, 50:837-840.
68. Gajdos P, Chevret S, Toyka K: Intravenous immunoglobulin for
myasthenia gravis.  Cochrane Database Syst Rev 2006,
19(2):CD002277. 
69. Huang C-S, Hsu H-S, Kao K-P, Huang M-H, Huang B-S: Intravenous
immunoglobulin in the preparation of thymectomy for
myasthenia gravis.  Acta Neurol Scand 2003, 108:136-138.
70. Gajdos P, Tranchant C, Clair B, Bolgert F, Eymard B, Stojkovic T, Atta-
rian S, Chevret S, Myasthenia Gravis Clinical Study Group: Treatment
of myasthenia gravis exacerbation with intravenous immu-
noglobulin 1g/kg versus 2g/kg: A randomized double blind
clinical trial.  Ann Neurol 2005, 62:1689-1693.
71. Tan E, Hajinazarian M, Bay W, Neff J, Mendel JR: Acute renal failure
resulting from intravenous immunoglobulin therapy.  Arch Neu-
rol 1993, 50:137-139.
72. Caress JB, Cartwright MS, Donofrio PD, Peacock JE: The clinical fea-
tures of 16 cases of stroke associated with administration of
IVIg.  Neurology 2003, 60:1822-1824.
73. Blalock A, Harvey AM, Ford FR, Lilienthal JL Jr: The treatment of
myasthenia gravis by removal of the thymus gland.  J American
Medical Association 1941, 117:1529-1533.
74. Blalock A: Thymectomy in the treatment of myasthenia gravis.
Report of twenty cases.  J Thorac Surg 1944, 13:316-339.
75. Wolfe GI, Kaminski HJ, Jaretzki A III, Swan A, Newsom-Davis J: Devel-
opment of a thymectomy trial in nonthymomatous myasthe-
nia gravis patients receiving immunosuppressive therapy.  Ann
NY Acad Sci 2003, 998:473-480.
76. A Multi-Center, Single-Blind, Randomized Study Comparing
Thymectomy to No Thymectomy in Non-Thymomatous
Myasthenia Gravis (MG) Patients Receiving Prednisone
(MGTX)   [http://www.soph.uab.edu/mgtx/]. Accessed 15 March 2007
77. Gronseth GS, Barohn RJ: Practice parameter: Thymectomy for
autoimmune myasthenia gravis (an evidence-based review):
Report of the Quality Standards Subcommittee of the Amer-
ican Academy of Neurology.  Neurology 2000, 55:7-15.
78. Perlo VP, Arnason B, Poskanzer D, Castleman B, Schwab RS, Osserman
KE, Papatestis A, Alpert L, Kark A: The role of thymectomy in the
treatment of myasthenia gravis.  Ann NY Acad Sci 1971,
183:308-315.
79. Rodriguez M, Gomez MR, Howard FM, Taylor WF: Myasthenia
gravis in children: Long-term follow-up.  Ann Neurol 1983,
13:504-510.
80. Mulder DG, Graves M, Hermann C: Thymectomy for myasthenia
gravis: Recent observation and comparisons with past experi-
ence.  Ann Thorac Surg 1989, 48:551-555.
81. Monden Y, Nakahara K, Kagotani K, Fujii Y, Nanjo S, Masaoka A,
Kawashima Y: Effects of preoperative duration of symptoms on
patients with myasthenia gravis.  Ann Thorac Surg 1984,
38:287-291.
82. Beghi E, Antozzi C, Batocchi AP, Cornelio F, Cosi V, Evoli A, Lombardi
M, Mantegazza R, Monticelli ML, Piccolo G, et al.:  Prognosis of
myasthenia gravis: A multicenter follow-up study of 844
patients.  J Neurol Sci 1991, 106:213-220.
83. Lanska DJ: Indications for thymectomy in myasthenia gravis.
Neurology 1990, 40:1828-1829.
84. Schumm F, Wietholter H, Fateh-Moghadam A, Dichgans J: Thymec-
tomy in myasthenia with pure ocular symptoms.  J Neurol Neu-
rosurg Psychiatry 1985, 48:332-337.
85. Jaretzki A III: Thymectomy for myasthenia gravis: Analysis of
the controversies regarding technique and results.  Neurology
1997, 48(Suppl 5):S52-S63.
86. Jaretzki A III, Steinglass KM, Sonett JR: Thymectomy in the man-
agement of myasthenia gravis.  Semin Neurol 2004, 24:49-62.
87. Jaretzki A III, Aarli JA, Kaminski HJ, Phillips LH, Sanders DB: Preoper-
ative preparation of patients with myasthenia gravis forestalls
postoperative respiratory complications after thymectomy.
Ann Thorac Surg 2003, 75:1068.
88. Bulkley GB, Bass KN, Stephenson GR, Diener-West M, George S, Reilly
PA, Baker RR, Drachman DB: Extended cervicomediastinal
thymectomy in the integrated management of myasthenia
gravis.  Ann Surg 1997, 226:324-334.
89. Oosterhuis HJ: The natural course of myasthenia gravis: A long-
term followup study.  J Neurol Neurosurg Psychiatry 1989,
52:1121-1127.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Orphanet Journal of Rare Diseases 2007, 2:44 http://www.OJRD.com/content/2/1/44
Page 13 of 13
(page number not for citation purposes)
90. Sellman MS, Mayer RF: Treatment of myasthenic crisis in late life.
South Med J 1985, 78:1208-1210.
91. Thomas CE, Mayer SA, Gungor Y, Swarup R, Webster EA, Chang I,
Brannagan TH, Fink ME, Rowland LP: Myasthenic crisis: Clinical
features, mortality, complications, and risk factors for pro-
longed intubation.  Neurology 1997, 48:1253-1260.
92. Pascuzzzi RM: Medications and myasthenia gravis: A reference
for health care professionals.   [http://myasthenia.org/docs/
MGFA_MedicationsandMG.pdf]. Accessed 15 March 2007
93. Osserman KE: Myasthenia gravis New York: Grune & Stratton;
1958:78-80. 
94. Simpson JA, Thomaides T: Treatment of myasthenia gravis: An
audit.  Q J Med 1987, 64:693-704.
95. Grob D: Natural history of myasthenia gravis.  In Myasthenia
gravis and myasthenic disorders Edited by: Engel AG. New York: Oxford
University Press; 1999:131-154. 